Devyser Diagnostics AB

Price Chart

Risk-Adjusted Performance

Devyser Diagnostics AB (DVYSR) Price Performance

Devyser Diagnostics AB (DVYSR) trades on Nasdaq Stockholm in SEK. The company is classified in the Healthcare sector under the Diagnostics & Research industry. The stock currently trades at SEK87.30, up 1.63% from the previous close.

Over the past year, DVYSR has traded between a low of SEK74.40 and a high of SEK157.80. The stock has lost 10.0% over this period. It is currently 44.7% below its 52-week high.

Devyser Diagnostics AB has a market capitalization of $1.45B.

About Devyser Diagnostics AB

Devyser Diagnostics AB (publ) engages in the development, manufacture, and sale of diagnostic kits and solutions for DNA testing within hereditary diseases, oncology, and post-transplantation monitoring in Sweden, rest of Europe, the Middle East, Africa, North and South America, and Asia. The company offers products in the areas of post-transplantation; thalassemia; breast, colorectal, and ovarian cancer; non-invasive fetal RHD screening prenatal testing, hereditary, cystic fibrosis, cardiovascular, male infertility, and rapid aneuploidy analysis, as well as accessories. Its products are used for targeted cancer treatment to diagnosis genetic diseases and transplant patient follow-up. The company also provides software programs for data processing and analysis, as well as interpretation of test results; and Amplicon Suite and Advyser software programs to screen markers and follow up samples for the same patient. Devyser Diagnostics AB (publ) was incorporated in 2004 and is based in Årsta, Sweden.

Compare Devyser Diagnostics AB

Side-by-side comparison against top Healthcare peers.